.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BN05_Covid19VirusLikeParticle.Covid19VirusLikeParticle .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BN05_Covid19VirusLikeParticle.Covid19VirusLikeParticle| name: | Covid19VirusLikeParticles | |
| ATC code: | J07BN05 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | liter/hour |
| other parameters in model implementation | ||
COVID-19 virus-like particles (VLPs) are non-infectious particles that mimic the structure of the SARS-CoV-2 virus without containing its genetic material. These VLPs are primarily used as experimental or approved vaccines for the prevention of COVID-19, helping induce immune responses similar to natural infection, but with a favorable safety profile. As of 2024, several VLP-based COVID-19 vaccines have been evaluated and some are approved in specific regions.
No direct pharmacokinetic (PK) study has been published reporting systemic PK measurements for COVID-19 virus-like particle vaccines in humans, as these vaccines are intended for intramuscular administration and primarily act locally to stimulate immune responses rather than reach significant systemic levels.